Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Katja Sockel, Annika Neu, Maren Goeckenjan, Markus Ditschkowski, Inken Hilgendorf, Nicolaus Kröger, Francis A. Ayuk, Friedrich Stoelzel, Jan Moritz Middeke, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Matthias Fante, Daniel Wolff, Thomas Luft, Julia Winkler, Kerstin Schäfer-Eckart, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christian Junghanss, Friederike Wortmann, Susann Winter, Helga Neidlinger, Catrin Theuser, Jan Beyersmann, Martin Bornhaeuser, Sandra Schmeller, Johannes Schetelig

Blood (2024) 144 (14): 1532–1542.

https://doi.org/10.1182/blood.2024024342

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Data Suggest Effectiveness of Allogeneic Mesenchymal Stromal (MSC-FFM) Cells in Ruxolitinib-Refractory Acute Graft-Versus-Host Disease

Blood (2023) 142 (Supplement 1): 4927.

https://doi.org/10.1182/blood-2023-174492

Published: 2023

Journal Articles

Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT

Blood (2023) 142 (Supplement 1): 3525.

https://doi.org/10.1182/blood-2023-174599

Published: 2023

Journal Articles

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 2236.

https://doi.org/10.1182/blood-2023-187273

Published: 2023

Journal Articles

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 657.

https://doi.org/10.1182/blood-2023-182823

Published: 2023

Journal Articles

Unrelated Donors below 35 Years of Age Should be Preferred over HLA-Matched Sibling Donors Older Than 50 Years for Patients with Myeloid Malignancies

Johannes Schetelig, Henning Baldauf, Carina Rave, Gesine Bug, Lutz Peter Hermann Mueller, Eva Wagner Drouet, Francis A. Ayuk, Wolfgang Andreas Bethge, Matthias Stelljes, Thomas Schröder, Desiree Kunadt, Katja Sockel, Jan Moritz Middeke, Daniel Fürst, Alexander H. Schmidt, Katharina Fleischhauer, Martin Bornhäuser

Blood (2023) 142 (Supplement 1): 1046.

https://doi.org/10.1182/blood-2023-180531

Published: 2023

Journal Articles

Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Ann-Kristin Schmälter, Myriam Labopin, Jurjen Versluis, Maria Pilar Gallego Hernanz, Matthias Eder, Peter A. Von Dem Borne, Gerard Socié, Patrice Chevallier, Edouard Forcade, Andreas Neubauer, Frederic Baron, Ali Bazarbachi, Gesine Bug, Arnon Nagler, Christoph Schmid, Jordi Esteve, Fabio Ciceri, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 3610.

https://doi.org/10.1182/blood-2023-182834

Published: 2023

Journal Articles

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Blood (2023) 142 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2023-174883

Published: 2023

Journal Articles

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Blood (2023) 142 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2023-182831

Published: 2023

Journal Articles

Clonal Hematopoiesis Is Common in Unrelated Stem Cell Donors but Has No Impact on Patient Outcome after Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 942.

https://doi.org/10.1182/blood-2023-179112

Published: 2023

Journal Articles

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 7089.

https://doi.org/10.1182/blood-2023-187095

Published: 2023

Journal Articles

Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3 -ITD and Wild Type NPM1 : A Report from the EBMT Acute Leukemia Working Party

Ali Bazarbachi, Myriam Labopin, Tobias Gedde-Dahl, Péter Reményi, Edouard Forcade, Nicolaus Kröger, Gerard Socie, Charles Craddock, Jean-Henri Bourhis, Jurjen Versluis, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Jean Elcheikh, Gesine Bug, Jordi Esteve, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 4897–4898.

https://doi.org/10.1182/blood-2022-165069

Published: 2022

Journal Articles

Interventional Antibiotic Treatment Replacing Antibiotic Prophylaxis during Allogeneic Hematopoietic Stem Cell Transplantation Is Safe and Feasible: A Single-Center Analysis

Rosa Toenges, Fabian Lang, Rakhshinda Ghaffar, Vera Schlipfenbacher, Julia Riemann, Salem Ajib, Khouloud Kouidri, Anjali Cremer, Weber Bodo, Thu Nguyen, Antje Knoch, Janne Vehreschild, Hubert Serve, Gesine Bug

Blood (2022) 140 (Supplement 1): 10478–10479.

https://doi.org/10.1182/blood-2022-163303

Published: 2022

Journal Articles

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

Ali Bazarbachi, Jacques-Emmanuel Galimard, Myriam Labopin, Iman Abou Dalle, Bruno Lioure, Johan A. Maertens, Maija Itälä-Remes, Maria Pilar Gallego Hernanz, Gesine Bug, Josep-Maria Ribera, Alain Gadisseur, Christoph Schmid, Xavier Poiré, Manuel Jurado Chacón, Frederic Baron, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 735–736.

https://doi.org/10.1182/blood-2022-162162

Published: 2022

Journal Articles

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Blood (2022) 140 (Supplement 1): 9–11.

https://doi.org/10.1182/blood-2022-159962

Published: 2022

Journal Articles

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Katja Sockel, Sandra Frank, Annika Neu, Markus Ditschkowski, Inken Hilgendorf, Mareen Goeckenjan, Friedrich Stoelzel, Jan Moritz Middeke, Nicolaus Kröger, Francis A. Ayuk, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Barbara Holler, Daniel Wolff, Thomas Luft, Wolf Roesler, Kerstin Schäfer-Eckart, Sabine Dressler, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christoph Wittke, Friederike Wortmann, Helga Neidlinger, Martin Bornhaeuser, Johannes Schetelig, on Behalf of the German Cooperative Transplant Study Group

Blood (2022) 140 (Supplement 1): 10563–10565.

https://doi.org/10.1182/blood-2022-162673

Published: 2022

Journal Articles

Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All- Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Inga Hund, Maria Hess, Julia Stomper, Gabriele Greve, Jan Mitschke, Christoph Niemöller, Tobias Ma, David Uhl, Felicitas R. Thol, Michael Heuser, Gesine Bug, Martina Crysandt, Lutz Peter Mueller, Andreas Neubauer, Justus Duyster, Hartmut Dohner, Melanie Boerries, Heiko Becker, Michael Luebbert

Blood (2022) 140 (Supplement 1): 3383–3384.

https://doi.org/10.1182/blood-2022-163220

Published: 2022

Journal Articles

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Blood (2021) 138 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2021-146468

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Blood (2021) 138 (Supplement 1): 173.

https://doi.org/10.1182/blood-2021-145167

Published: 2021

Journal Articles

Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission

Blood (2021) 138 (Supplement 1): 1783.

https://doi.org/10.1182/blood-2021-145100

Published: 2021

NARROW

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Real-World Data Suggest Effectiveness of Allogeneic Mesenchymal Stromal (MSC-FFM) Cells in Ruxolitinib-Refractory Acute Graft-Versus-Host Disease

Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Unrelated Donors below 35 Years of Age Should be Preferred over HLA-Matched Sibling Donors Older Than 50 Years for Patients with Myeloid Malignancies

Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Clonal Hematopoiesis Is Common in Unrelated Stem Cell Donors but Has No Impact on Patient Outcome after Hematopoietic Stem Cell Transplantation

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3 -ITD and Wild Type NPM1 : A Report from the EBMT Acute Leukemia Working Party

Interventional Antibiotic Treatment Replacing Antibiotic Prophylaxis during Allogeneic Hematopoietic Stem Cell Transplantation Is Safe and Feasible: A Single-Center Analysis

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All- Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only